Commonwealth Equity Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.29M Sell
12,131
-756
-6% -$132K ﹤0.01% 1891
2025
Q4
$2.19M Buy
12,887
+769
+6% +$118K ﹤0.01% 1892
2025
Q3
$1.6M Buy
12,118
+810
+7% +$97.2K ﹤0.01% 2201
2025
Q2
$1.2M Sell
11,308
-2,899
-20% -$315K ﹤0.01% 2415
2025
Q1
$1.76M Buy
14,207
+1,323
+10% +$173K ﹤0.01% 1998
2024
Q4
$1.59M Sell
12,884
-784
-6% -$92.4K ﹤0.01% 2036
2024
Q3
$1.52M Buy
13,668
+146
+1% +$16K ﹤0.01% 2022
2024
Q2
$1.44M Buy
13,522
+364
+3% +$40K ﹤0.01% 2005
2024
Q1
$1.58M Buy
13,158
+2,318
+21% +$284K ﹤0.01% 1927
2023
Q4
$1.33M Buy
10,840
+767
+8% +$95.7K ﹤0.01% 1969
2023
Q3
$1.3M Buy
10,073
+962
+11% +$128K ﹤0.01% 1891
2023
Q2
$1.13M Buy
9,111
+47
+0.5% +$6.32K ﹤0.01% 2008
2023
Q1
$1.33K Sell
9,064
-300
-3% -$44.4K ﹤0.01% 1847
2022
Q4
$1.49M Sell
9,364
-96
-1% -$14.1K ﹤0.01% 1688
2022
Q3
$1.26M Sell
9,460
-30
-0.3% -$4.56K ﹤0.01% 1740
2022
Q2
$1.48M Sell
9,490
-677
-7% -$104K ﹤0.01% 1608
2022
Q1
$1.58M Buy
10,167
+447
+5% +$64.9K ﹤0.01% 1647
2021
Q4
$1.24M Sell
9,720
-10,475
-52% -$1.38M ﹤0.01% 1832
2021
Q3
$2.63M Buy
20,195
+8,672
+75% +$1.31M 0.01% 1265
2021
Q2
$2.05M Buy
11,523
+7,397
+179% +$1.28M 0.01% 1407
2021
Q1
$678K Sell
4,126
-10,523
-72% -$1.73M ﹤0.01% 2082
2020
Q4
$2.42M Buy
14,649
+11,559
+374% +$1.72M 0.01% 1118
2020
Q3
$440K Sell
3,090
-354
-10% -$43.9K ﹤0.01% 2058
2020
Q2
$380K Sell
3,444
-920
-21% -$102K ﹤0.01% 2091
2020
Q1
$435K Buy
4,364
+437
+11% +$56.5K ﹤0.01% 1789
2019
Q4
$586K Buy
3,927
+816
+26% +$111K ﹤0.01% 1782
2019
Q3
$398K Sell
3,111
-227
-7% -$30.4K ﹤0.01% 2001
2019
Q2
$475K Buy
3,338
+92
+3% +$12.4K ﹤0.01% 1842
2019
Q1
$464K Buy
3,246
+290
+10% +$37.8K ﹤0.01% 1800
2018
Q4
$366K Sell
2,956
-244
-8% -$36.2K ﹤0.01% 1868
2018
Q3
$538K Sell
3,200
-309
-9% -$53.1K ﹤0.01% 1749
2018
Q2
$605K Buy
3,509
+226
+7% +$36.9K ﹤0.01% 1618
2018
Q1
$495K Sell
3,283
-113
-3% -$16.6K ﹤0.01% 1720
2017
Q4
$457K Sell
3,396
-723
-18% -$100K ﹤0.01% 1752
2017
Q3
$602K Sell
4,119
-25
-0.6% -$3.78K ﹤0.01% 1494
2017
Q2
$644K Sell
4,144
-1,500
-27% -$229K ﹤0.01% 1402
2017
Q1
$819K Sell
5,644
-662
-10% -$86.2K 0.01% 1223
2016
Q4
$688K Buy
6,306
+358
+6% +$39.9K 0.01% 1231
2016
Q3
$723K Buy
5,948
+267
+5% +$36K 0.01% 1167
2016
Q2
$803K Buy
5,681
+230
+4% +$33.9K 0.01% 1094
2016
Q1
$712K Sell
5,451
-92
-2% -$11.5K 0.01% 1122
2015
Q4
$779K Buy
5,543
+330
+6% +$45.7K 0.01% 1057
2015
Q3
$692K Buy
5,213
+712
+16% +$123K 0.01% 1074
2015
Q2
$792K Sell
4,501
-120
-3% -$21.6K 0.01% 1084
2015
Q1
$798K Sell
4,621
-279
-6% -$47.9K 0.01% 1071
2014
Q4
$802K Buy
4,900
+686
+16% +$114K 0.01% 1012
2014
Q3
$677K Buy
4,214
+770
+22% +$118K 0.01% 1064
2014
Q2
$506K Sell
3,444
-1,405
-29% -$195K 0.01% 1235
2014
Q1
$672K Sell
4,849
-2,282
-32% -$343K 0.01% 1026
2013
Q4
$902K Sell
7,131
-207
-3% -$21.4K 0.01% 822
2013
Q3
$675K Buy
7,338
+190
+3% +$15.3K 0.01% 924
2013
Q2
$491K Buy
+7,148
New +$437K 0.01% 1031

Other funds holding JAZZ

Commonwealth Equity Services's JAZZ Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Jazz Pharmaceuticals (JAZZ) stake by 5.9% in Q1 2026, selling an estimated $132K and leaving 12,131 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1891.

Commonwealth Equity Services first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.63M in Q3 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Commonwealth Equity Services held 12,131 shares of Jazz Pharmaceuticals worth $2.29M as of Q1 2026.
  • Commonwealth Equity Services sold 756 Jazz Pharmaceuticals shares in Q1 2026, an estimated $132K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #1891 holding.
  • Commonwealth Equity Services first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Commonwealth Equity Services's Jazz Pharmaceuticals position peaked at $2.63M in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.